 |
University of Pennsylvania Medical Center
Pulmonary, Allergy & Critical Care Division
Translational Research Building
125 S. 31st Street
Philadelphia, PA 19104-3403
tel.: (215) 573-9861
fax.: (215) 573-4469
email: krymskay@mail.med.upenn.edu
- PhD: Moscow State University, Russia
- Postdoctoral Fellowship: University of Pennsylvania
Dr. Krymskaya's research interests are in the signal transduction
mechanisms regulating cell growth, proliferation and migration.
Her basic science studies are translated into the identifying
therapeutic targets to treat rare lung cancer lymphangioleiomyomatosis
(LAM), pulmonary arterial hypertension and asthma. Dr. Krymskaya
discovered the function of tumor suppressor TSC2 as a negative
regulator of S6K1, and S6K1 as a molecular target to treat
LAM disease. This discovery was immediately transferred
to the clinic, and the first clinical trail for LAM patients
started at the Children’s Hospital Medical Center
in Cincinnati, OH. For this achievement Dr. Krymskaya has
honored by The Science Advancement Award from The LAM Foundation.
Goncharova, E. A., Goncharov, D. A., and V. P. Krymskaya:
Assay for in vitro monitoring of human airway smooth muscle
(ASM) and human pulmonary arterial vascular smooth muscle
(VSM) cell migration. Nature Protocols 1(6): 2933-2939,
Dec 2006.
Goncharova, E.A., Lim, P., Goncharov, D.A., Eszterhas, A.,
Panettieri, R.A., Jr. and Krymskaya, V.P.: Assay for in
vitro monitoring of proliferation of human airway smooth
muscle (ASM) and human pulmonary arterial vascular smooth
muscle (VSM) cells. Nature Protocols 1(6): 2905-2908, Dec
2006.
Goncharova, EA and Krymskaya, VP: Pulmonary Lymphangioleiomyomatosis
(LAM): Progress and Current Challenges Journal of Cellular
Biochemistry. Wiley-Liss, Inc. Vol. Published On-line on
May 31, 2007.
Krymskaya, VP: Smooth Muscle-Like Cells in Pulmonary Lymphangioleiomyomatosis
(LAM). Proceedings of the American Thoracic Society Vol.
In Press, 2007.
Vera P. Krymskaya: Targeting Phosphatidylinositol 3-Kinase
in Airway Smooth Muscle: Rationale and Promise. BioDrugs.
Adis International, Ltd, 21(2): 85-95, 2007.
revised 7/07 |